

## Acute Coronary Syndromes Committee meeting 9

**Date:** 18/6/2019

**Location:** Holiday Inn Regent's Park, Carburton Street, London W1W 5EE

**Minutes:** Final

<b>Committee members present:</b>	
Margaret Lally (Chair)	(Present for notes 1 – 6)
Simon Corbett (Topic adviser)	(Present for notes 1 – 6)
Farrah Al-Ghita	(Present for notes 1 – 6)
Christopher Cassidy	(Present for notes 1 – 6)
Ewan Gittins	(Present for notes 1 – 6)
Lance Goodman	(Present for notes 1 – 6)
Muhammad Murad Khan	(Present for notes 1 – 6)
Alun Roebuck	(Present for notes 1 – 6)
Alex Sharp	(Present for notes 1 – 6)
Neil Swanson	(Present for notes 1 – 6)

<b>In attendance:</b>		
Rupert Franklin	Senior Guidelines Commissioning Manager	(Present for notes 1 – 6)
Annabelle Davies	Health Economist	(Present for notes 1 – 6)
Saoussen Ftouh	Senior Research Fellow	(Present for notes 1 – 6)
Bernard Higgins	Clinical Director & Guideline Lead	(Present for notes 1 – 6)
Kate Lovibond	Health Economics Lead	(Present for notes 5 - 6)
Nancy Pursey	Senior Project Manager	(Present for notes 1 – 6)

<b>Apologies:</b>	
Jill Cobb	Information Specialist, NGC
Agnes Cuyas	Information Specialist, NGC
Sedina Lewis	Senior Research Fellow, NGC

## **1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the 9th meeting of the Acute Coronary Syndromes guideline committee. The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Review the evidence for optimal duration of beta-blockers for adults without left ventricular dysfunction after myocardial infarction.
- Provide an update on the methods for the model for dual anti-platelet therapy.

## **2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were duration of beta blockers and choice of dual antiplatelet therapy.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

CC declared:

- a direct financial interest - travel, registration and accommodation only support from Abbott to attend the Heartmate 3 meeting on left ventricular assist devices and advanced heart failure in June 2019
- an indirect financial interest - Boston Scientific have provided financial support for a fellow in cardiac devices and heart failure in his Department (June 2019 – June 2021)

The chair confirmed that the interests declared did not affect matters under discussion. RF stated that the Abbott support is not a conflict as it was reimbursement for travel and accommodation only.

NP will update the declarations of interest register.

AR declared that his Trust has hosted a conference for advanced clinical practitioners with grants from Novartis and Astra Zeneca. This was not directly connected to cardiology or AR and it was agreed this this is not a conflict.

The Chair and Guideline lead noted that the interests declared did not prevent the attendees from fully participating in the meeting.

## **3. Minutes of last meeting**

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. A minor correction was made to the numbering of recommendations and agenda items. The Committee agreed that the minutes were a true and accurate account of the meeting.

#### **4. Evidence review: optimum duration of beta blockers**

The Chair introduced Saoussen Ftouh, Senior Research Fellow, and Annabelle Davies, Health Economist, who gave a presentation on the clinical and cost effectiveness evidence for the following review question: What is the optimal duration of beta-blocker therapy to improve outcomes for adults without left ventricular dysfunction after myocardial infarction?

The Committee then discussed the evidence and draft recommendations.

The Committee agreed that this topic is not suitable for a patient decision aid. The Committee discussed other suitable topics (early angiography for NSTEMI). ML will co-ordinate drafting of a table for inclusion in the guideline that sets out key benefits and drawbacks.

#### **5. Presentation: model for dual anti-platelet therapy**

The Chair introduced Annabelle Davies, Health Economist, who gave a presentation on the modelling methods for the dual antiplatelet therapy model.

AD will schedule a teleconference to discuss the model results in August.

#### **6. Any other business**

None

**Date of next meeting:** 16/07/2019

**Location of next meeting:** Royal College of Physicians, London